Who are Verquvo's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Adempas, Adempas, Riociguat (Adempas), Riociguat Oral Product, Riociguat Pill, SOC: Soluble guanylate cyclase stimulator.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vericiguat.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Verquvo — Competitive Intelligence Brief

Verquvo (VERICIGUAT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Soluble Guanylate Cyclase Stimulator [EPC]. Area: Cardiovascular.

marketed Soluble Guanylate Cyclase Stimulator [EPC] Guanylate cyclase soluble subunit beta-1 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Verquvo (VERICIGUAT) — Merck & Co.. Verquvo works by stimulating the enzyme guanylate cyclase to increase levels of a molecule called cGMP, which helps to relax blood vessels and improve heart function.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Verquvo TARGET	VERICIGUAT	Merck & Co.	marketed	Soluble Guanylate Cyclase Stimulator [EPC]	Guanylate cyclase soluble subunit beta-1	2021-01-01
Adempas	RIOCIGUAT	Bayer	marketed	Soluble Guanylate Cyclase Stimulator [EPC]	Guanylate cyclase soluble subunit beta-1	2013-01-01
Adempas	Adempas	University of Colorado, Denver	marketed		Guanylate cyclase soluble subunit beta-1, cAMP-specific 3',5'-cyclic phosphodiesterase 7B
Riociguat (Adempas)	Riociguat (Adempas)	Chinese University of Hong Kong	marketed	Soluble guanylate cyclase stimulator	Soluble guanylate cyclase (sGC)
Riociguat Oral Product	Riociguat Oral Product	University of Calgary	marketed	Soluble guanylate cyclase stimulator	Soluble guanylate cyclase (sGC)
Riociguat Pill	Riociguat Pill	University of Arizona	phase 3	Soluble guanylate cyclase stimulator	Soluble guanylate cyclase (sGC)
SOC: Soluble guanylate cyclase stimulator	SOC: Soluble guanylate cyclase stimulator	Actelion	phase 3	Soluble guanylate cyclase stimulator	Soluble guanylate cyclase (sGC)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Soluble Guanylate Cyclase Stimulator [EPC] class)

Bayer · 1 drug in this class
Merck & Co. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Verquvo — Competitive Intelligence Brief. https://druglandscape.com/ci/vericiguat. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab